 MENLO PARK, Calif., April 19, 2021 GLOBE NEWSWIRE -- 180 Life Sciences Corp. NASDAQ: ATNF 180 Life Sciences or the Company, a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, announced today that it received an expected letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC Nasdaq stating that the Company is not in compliance with Nasdaq Listing Rule 5250c1 because it has not yet filed its Annual Report on Form 10-K for the year ended December 31, 2020 the 2020 Form 10-K with the Securities and Exchange Commission the SEC. The Nasdaq notification letter has no immediate effect on the listing or trading of the Companys common stock on the Nasdaq Capital Market. 